Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : NPSP NPS Pharmaceutical -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (43)	12/23/1999 1:50:00 AM
From: scaram(o)uche	Respond to of 363

[ parking ] Certain David Clark won't mind me posting this....... Dear Mr. Harmon: Thanks for the query. We will update the fact sheet on the web site to reflect post merger shares outstanding. In the meantime, NPS has approximately 13.0 million shares outstanding and we have issued 6.5 million shares to Allelix shareholders for a post merger total of about 19.5 million shares outstanding. Another 1.0 million shares have been reserved for holders of Allelix options, warrants, and preferred stock. I hope this is helpful. Please contact me again if you have further questions. David Clark VP, Corporate Communications and Business Development NPS Pharmaceuticals, Inc.

To: scaram(o)uche who wrote (43)	12/23/1999 12:22:00 PM
From: biowa	Read Replies (1) \| Respond to of 363

Rick, <<He must have warm and fuzzies about the Amgen trial>> I've heard recent rumors that that may be the case. AMGN has been in PII trials for secondary HPT since 2Q98 and primary HPT since 3Q98 with the second-generation candidate; seems they should be due to wrap soon. At the risk of sounding like a cheerleader, even at $7 there is huge upside over the next year. 2000 could be a big news year, especially in clinical progress. IMO, we could see: HPT (secondary & primary) PII results Osteoprosis ALX 1-11 PIII trial start (announced for 2Q00) GI (short bowel syndrome) ALX 0600 PII results Epilepsy (& perhaps bipolar) NPS 1776 additional PI results, partner and perhaps PII start Stroke (& perhaps trauma) NPS 1506 perhaps partner and PII start? Dementia ALE 26015 additional PI results and perhaps PII start Migraine ALX 0646 perhaps PII start AND on my christmas wish list: Osteoporosis (w/ SKB) a calcilytic candidate and IND (pure spec.) None of this is endorsed by NPSP or Allelix (other than ALX 1-11 PIII), and is purely speculation. With their announced annual burn rate goal of $10-12 million, unless some of the unpartnered programs are partnered I don't see how they will all progress. The status of 1506 in particular seems to be an uncertainty. In other words - for lurkers - this is a road map, DO YOUR DUE DILIGENCE. And of course, there are several analysts on the tube today calling for a market correction of 20% in mid-January. Here's to a Happy NPSP year, biowa